MemorialCare Long Beach Center Joins Global Fight Against Covid
As part of an ongoing global study, MemorialCare Long Beach Center has administered the antiviral drug Remdesivir to three patients as a possible treatment for Covid. This news comes closely after Gilead, a biotech company based out of the California Bay Area,...
FDA Allows Outsourcing for Drugs in Short Supply Due to Covid
The FDA announced on Thursday (4/16) it was temporarily allowing compounding for necessary hospital drugs due to the mass shortage from Covid. The majority of the 13 commonly used drugs listed in the policy are anesthetic or analgesic drugs, which helps support...
AAMI Drafts Emergency Respirator and Ventilator Medical Devices Guidance in Response to Shortage Due to COVID-19
The Association for the Advancement of Medical Instrumentation (AAMI) released four guidelines yesterday (4/14) from their COVID-19 response team about medical device such as respirators and ventilators to help combat the viral outbreak. The team is made up of...
Face Masks, Social Distancing, and Sheltering in Place: The New Landscape of Global Health in the Fight Against Covid
As Covid continues to spread across the globe, affecting Italy, Spain, and the United States most severely, governmental agencies continue to fight the spread of misinformation surrounding the virus by issuing health safety recommendations. The importance of social...
China Creating a Framework on Real-World Evidence
Purpose of Real-World Evidence/Real-World Data Real-World Evidence is critical for designing more effective treatments. For example, to test new treatments, pharmaceutical companies adopt a method called "Randomized Controlled Trial" (RCT). There are two design groups...
China Finalized the Trade Agreement for Patent Drug with the U.S.
Trade Agreement On January 16, 2020 the U.S. and China finalized the trade agreement that specifies the patent protection rules for drugs. Under the patent protection, biopharmaceutical companies can fill out an application and the term of each new patent is 20 years....
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com